Newsroom

-biostrand now offers a customizable application programming interface (api) with its new software offering, lensai api, featuring the ability to integrate sizable databases and electronic health records with large language models. -biostrand’s novel software is rapidly and directly integrable into pharmaceutical, healthcare, and technology companies to enhance drug discovery capabilities. -this proprietary software provides the integration of electronic health records, enhancing ai-driven drug discovery and development for industry professionals. victoria, british columbia, june 10, 2024 - immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, today announces the commercial release of lensai api, hereafter referred to as the ‘software’, by its subsidiary, biostrand. this advanced ai-driven software solution is available immediately. more details on this new offering will be unveiled today at 2:00 pm et, with an additional presentation, live demonstration, and interview at 6:30 pm et, all taking place at the intersystems global summit 2024. this premier event, which attracts over 1,200 industry leaders from more than 28 countries, showcases the latest innovations in the field. ipa, the #1 ranked contract research organization by roots analysis2, serves 19 of the top 20 global pharmaceutical companies and over 600 clients in the pharmaceutical and biotech industries. leveraging feedback from these long-term relationships, the development of this ai-driven software is in direct response to meeting ongoing industry pain points and needs. these new software capabilities demonstrate innovation by combining biostrand’s patented lensai technology with electronic health records through a customizable interface to enable unprecedented research and drug discovery capabilities. dr. dirk van hyfte is leading the launch of this exciting integration, enabling industry professionals to quickly and easily access and merge patient data, company research data, and extensive life science databases. through this new release, corporations will be able to analyze major datasets related to generating novel and potentially safer and more effective drugs, as the biostrand team continues to develop a full lensai data management platform, expected to be released in q1/q2 2025. dr. dirk van hyfte stated, "we have received significant interest in our new technology from large healthcare, pharmaceutical, and technology companies. they are keen on accessing our unique capabilities through an integration that enables them to benefit directly from biostrand's novel applications for data analysis and cutting-edge drug discovery. the company regards the commercial launch of this pioneering software as its most significant ai breakthrough to date, poised to significantly enhance global drug discovery and development processes. by integrating biostrand’s software with electronic health records, and adding biostrand’s application programming interface, we have surpassed internal timelines and milestones, supporting the rapid commercialization of these high-demand capabilities." these new commercial capabilities will significantly enhance biostrand’s ability to commercialize: partnerships with large companies: major pharmaceutical, technology, and healthcare companies will be able to rapidly leverage biostrand’s new software capabilities through partnerships that may include upfront payments, clinical milestones and commercial royalties. subscription model: biostrand is offering a subscription service that enables a wide range of technology, healthcare, and pharmaceutical companies to access biostrand’s unique capabilities using integration of the software into their existing platforms, with a strong probability of enhancing their drug discovery and development programs. in light of the upcoming presentation at the intersystem’s global summit 2024, dr. dirk van hyfte has requested that the live podcast, media events, and interviews be recorded and made available to the public whenever possible. we also encourage everyone who can attend the live demonstration at the summit to join and support this exciting public commercial launch. you can register: intersystems global summit 2024 registration. investor contact: investors@ipatherapeutics.com 1www.strategyand.pwc.com/de/en/industries/pharma-life-science/re-inventing-pharma-with-artificial-intelligence.html 2roots 2022, antibody discovery services and platforms market (4th edition), 2021-2035; pp.118 about immunoprecise antibodies ltd. the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

victoria, british columbia (canada), march 28, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), intersystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with immunoprecise antibodies ltd. (ipa) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration. this collaboration integrates the new vector search capability of the intersystems iris® data platform with ipa’s subsidiary biostrand's lensai platform, setting a new standard for ai-driven applications in healthcare and life sciences. this collaboration signifies a leap in technological advancement for addressing challenges with increasing volumes of data that the healthcare and life sciences industries are contending with today. with the global ai market projected to grow to over $1.3 trillion by 2032, the collaboration between intersystems and ipa highlights both companies' commitment to innovation, excellence, and the development of solutions that not only meet the current needs of the healthcare and life sciences sectors but also anticipate future challenges, with additional client solutions and developments expected as vector search and lensai redefine the interaction between data and ai applications in healthcare and life sciences. “as the latest addition to the intersystems iris data platform, vector search has helped to supercharge the identification and creation of novel drug compounds, significantly reducing r&d timelines from development to commercialization” said scott gnau, head of global data platforms at intersystems. “we look forward to seeing how vector search within intersystems iris empowers other developers to build additional ai applications on our platform.” "by combining intersystem’s vector search with ipa's lensai, we're empowering developers and researchers in the life sciences with unparalleled tools for extracting value and insights from complex datasets, driving forward the potential for ai in every application within the healthcare and life sciences sectors," said dirk van hyfte md, phd, co-founder and head of innovation of biostrand. "we are at the cusp of a new era in ai-driven applications, where the integration of sophisticated data analysis tools like vector search with the deep biological insights provided by lensai can lead to breakthroughs in patient care and treatment methodologies.” vector search and lensai: a synergistic integration this innovative integration marries the precision of vector search, which enables efficient and accurate retrieval of relevant information from massive datasets using vector embeddings, with the depth of analysis provided by lensai universal foundation ai model and biostrand's patented hyft technology. the result is a platform that offers unmatched capabilities in accessing, analyzing, and leveraging complex biological data for drug discovery, understanding disease mechanisms, and beyond. advancing healthcare and life sciences the collaboration between intersystems and ipa leverages the strengths of both platforms to offer several transformative benefits: precision and depth in data analysis: the integration enables more precise, semantically rich searches across vast repositories of unstructured biological data, uncovering insights that were previously difficult to obtain. accelerated drug discovery and development: researchers can now leverage the combined power of vector search and lensai to identify novel therapeutic targets more quickly, streamlining the drug discovery process and reducing the time from discovery to clinical trials. enhanced integration and scalability: by providing lensai capabilities within the intersystems iris data platform, companies in healthcare and life sciences gain a tool that seamlessly integrates with their existing infrastructure, offering scalability and enhanced performance without compromising security. about intersystems intersystems is a leading provider of next-generation solutions for enterprise digital transformations in the healthcare, finance, manufacturing, and supply chain sectors. its cloud-first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe. intersystems offers a range of software, including its flagship data platform software, intersystems iris, and a set of industry specific applications that speed and simplify the process of making data “ai ready.” intersystems is committed to excellence through its award-winning, 24×7 support for customers and partners in more than 80 countries. privately held and headquartered in cambridge, massachusetts, intersystems was established in 1978 and now has 39 offices in 28 countries worldwide. for more information, please visit intersystems.com. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, healthcare, integration and / or success of lensai with vector search, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology and vector search may not have the expected results, risks that the expected healthcare benefits won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

significant throughput of lsa to advance ipa’s diversity- and data-driven drug development and to enrich lensai™. victoria, british columbia (canada), march 20, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the lsa® instrument platform from carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. this instrument allows for high throughput surface plasmon resonance-based antibody characterizations thereby significantly increasing the company’s capacity in performing various label-free protein interaction analyses including best-in-class kinetics, epitope binning, quantitation, epitope mapping, and blocking/neutralization assays. ipa remains committed to expanding its contract research organization (cro) capabilities and leveraging technology to drive innovation and efficiency, particularly in ai-driven drug design. carterra’s lsa instrument delivers significant throughput in short time frames requiring only small sample volumes. this fits well with the company’s established high throughput capabilities and diversity- and data-driven drug discovery, delivering huge amounts of valuable data points at an early-stage to advance the lead triaging process. the efficiency gain resulting from the acquisition will not only expedite the company’s in vitro characterizations for clients and partners, but also rapidly fuels lensai with valuable data sets to optimize models for next gen in silico drug discovery and development utilizing their proprietary hyfts to aggregate and integrate biological data. “the significance of our lensai technology extends beyond just the creation of an advanced tool,” says ipa’s chief executive officer and president, jennifer bath, phd. “it represents a strategic move to capture the growing interest in and huge potential of ai-driven drug discovery and digital biology. complementing our well-established high throughput antibody discovery, production, and screening capabilities, carterra’s lsa gets us closer to making ours the fastest and most cost-effective drug discovery workflow.” “we couldn’t be more excited to join with ipa in changing the way drugs are discovered,” said tim germann, chief commercial officer at carterra. “the lsa has made the use of ai in antibody discovery a reality; nothing generates more data in as little time to train ai/ml engines.” about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. ipa contact: info@ipatherapeutics.com about carterra, inc.: carterra, inc. is a privately held company. its ht-spr technology provides large-molecule and small-molecule drug discovery customers with screening and characterization throughput and functionality that scales with omics-level applications, condensing months of work down to days. our solutions have enabled multiple therapeutics and breakthrough research and helped academic and translational researchers and biopharmaceutical companies in oncology, immunology, neuroscience, and more. carterra is based in salt lake city, utah, and has customer experience centers in san francisco, salt lake city, boston, manchester, england, and munich, germany. carterra products are available in asia-pacific and oceania through our exclusive distributor, revvity. to learn more, visit www.carterra-bio.com or connect with us on linkedin or x (twitter). carterra contact: cheri salazar sr. marketing manager +1 (408) 594-9400 forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments will not be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

company received official notice from the european patent office (epo) for the decision to grant its patent application on april 5th, 2023. the patent was initially filed february 7th, 2020. patent application covers a method to efficiently handle mass biological sequence information. related patents pending in other countries, favorable outcomes anticipated victoria, british colombia march 27, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), the parent company of biokey and affiliate of biostrand, announced today that the epo has issued a “decision to grant” for biokey’s patent application covering the company’s hyft® technology used to organize and analyze biological sequence information. the hyft technology and methodology provide a novel way to efficiently tap into sequence information, allowing the extraction and use the relevant information therein to address the current problems in omics data integration and analysis. the hyft technology serves as the core of the biostrand’s lensai integrated technologytm platform which provides cutting-edge data solutions and antibody discovery. the patent will provide biostrand’s lensai integrated technology with broad protection, further strengthening the company’s patent portfolio position and enabling exclusive access to the hyft technology. the company anticipates favorable outcomes in other countries as well, as many patent offices worldwide consider the status of related european cases to be highly relevant to the decision to grant patents. “this is a significant and exciting decision by the epo, and we view this announcement as a recognition of biostrand’s important contributions to the fields of omic data integration and analysis, fields paramount to the future of cancer research, precision medicine, biomarker identification, and novel drug discovery and development,” stated dr. jennifer bath, ceo of ipa. “this patent provides protection for biokey’s hyft technology, which will give scientists the ability to advance the development of safer and more effective therapies for the toughest medical challenges we face today.” the hyft technology hyft technology is a way of organizing information about the natural world by creating connections between patterns found in living things, called hyfts. these patterns can link genetic sequences to their structures and functions, as well as to other information such as scientific papers and medical records. the output, the hyft knowledge graph, contains over 660 million patterns and 25 billion connections, and is continuously updated with new information. this provides a powerful tool for exploring relationships in the natural world, which can be used for research and applications in medicine and other fields. the hyft graph is unique in its explicit representation of information from the whole biosphere, and it provides a transparent intermediate layer between sequences and predictions that allows for new knowledge to be extracted without the limitations of a black box. hyft-based technologies have numerous applications in various fields beyond just data integration, organization, and analysis, such as drug immunogenicity testing, drug discovery, and natural language processing (nlp). these applications have the potential to accelerate the drug development process and improve patient outcomes. in the field of immunogenicity, hyfts can help predict parts of a molecule that may trigger an immune response. this information is crucial in therapeutic and vaccine development, as it helps identify potential safety concerns before they become problematic. moreover, hyfts can predict off-target effects, which occur when a drug or therapy affects unintended targets in the body. early identification of potential off-target effects allows researchers to design safer and more effective treatments. in drug discovery, hyft-based technologies have multiple potential applications, including: toxicity prediction: by linking genetic sequences to toxicological data, hyfts can predict the toxicity of potential drug candidates, helping researchers identify compounds likely to cause adverse effects before entering clinical trials. drug repurposing: hyfts can identify existing drugs for repurposing by linking genetic sequences to known targets and functions, accelerating the drug discovery process by finding compounds already approved for other indications. clinical trial design: hyfts can optimize clinical trial design by linking genetic sequences to patient data and clinical outcomes, identifying patient subgroups more likely to benefit from specific treatments, and enabling personalized and efficient clinical trials. biomarker discovery: by linking genetic sequences to disease-specific phenotypes, hyfts can identify biomarkers of disease, helping to identify at-risk patients and enable earlier diagnosis and treatment. another application of hyft-based technologies is tied to nlp, which involves analyzing and extracting information from written or spoken language. hyfts can link text-based information, such as scientific papers or medical records, to specific genetic sequences or structures, facilitating more efficient and accurate analysis. this is particularly valuable in genomics and personalized medicine, where vast amounts of textual data must be processed and analyzed to identify potential therapies or treatments. the company believes that the utilization of hyft-based technologies in drug discovery and other fields shows great promise for expediting the drug development process and enhancing patient outcomes. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, biokey bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the potential applications of hyft-based technologies and the prediction capabilities and speed of the discovery processes. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of the above-mentioned hyfts may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies